Vanguard Group Inc. Has $111.40 Million Holdings in Cogent Biosciences, Inc. $COGT

Vanguard Group Inc. increased its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) by 18.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,757,662 shares of the technology company’s stock after buying an additional 1,234,711 shares during the quarter. Vanguard Group Inc. owned 6.81% of Cogent Biosciences worth $111,400,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of COGT. Mirae Asset Global Investments Co. Ltd. boosted its position in Cogent Biosciences by 22.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,401 shares of the technology company’s stock valued at $78,000 after buying an additional 1,003 shares in the last quarter. ProShare Advisors LLC grew its holdings in Cogent Biosciences by 4.1% during the 2nd quarter. ProShare Advisors LLC now owns 26,021 shares of the technology company’s stock worth $187,000 after acquiring an additional 1,020 shares during the last quarter. Corton Capital Inc. increased its position in Cogent Biosciences by 6.4% in the 2nd quarter. Corton Capital Inc. now owns 17,438 shares of the technology company’s stock valued at $125,000 after acquiring an additional 1,046 shares in the last quarter. CWM LLC raised its stake in shares of Cogent Biosciences by 25.3% in the third quarter. CWM LLC now owns 5,582 shares of the technology company’s stock worth $80,000 after acquiring an additional 1,126 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its position in Cogent Biosciences by 41.4% in the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock valued at $33,000 after buying an additional 1,333 shares during the last quarter.

Insider Buying and Selling

In other news, insider Evan Kearns sold 65,000 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $38.70, for a total transaction of $2,515,500.00. Following the sale, the insider owned 109,398 shares in the company, valued at $4,233,702.60. This represents a 37.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Fairmount Funds Management Llc sold 3,500,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $36.40, for a total value of $127,400,000.00. Following the completion of the sale, the director directly owned 5,503,418 shares of the company’s stock, valued at approximately $200,324,415.20. The trade was a 38.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,737,642 shares of company stock worth $136,600,345. Insiders own 7.29% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on COGT. Wall Street Zen lowered Cogent Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Cogent Biosciences in a report on Monday, December 29th. UBS Group raised shares of Cogent Biosciences to a “strong-buy” rating in a report on Wednesday, January 7th. Robert W. Baird set a $35.00 target price on shares of Cogent Biosciences in a research report on Thursday, February 19th. Finally, Leerink Partners raised their price target on Cogent Biosciences from $18.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cogent Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Cogent Biosciences Trading Down 0.6%

COGT opened at $37.02 on Thursday. The firm’s fifty day simple moving average is $37.44 and its 200 day simple moving average is $27.73. Cogent Biosciences, Inc. has a 12 month low of $3.72 and a 12 month high of $43.73. The stock has a market capitalization of $6.01 billion, a P/E ratio of -17.14 and a beta of 0.47. The company has a current ratio of 14.23, a quick ratio of 14.23 and a debt-to-equity ratio of 0.41.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings data on Tuesday, February 17th. The technology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, research analysts anticipate that Cogent Biosciences, Inc. will post -2.42 EPS for the current fiscal year.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.